ProQR Therapeutics NV (PRQR.OQ)
PRQR.OQ on NASDAQ Stock Exchange Global Market
3.50USD
12:02pm EDT
3.50USD
12:02pm EDT
Change (% chg)
$-0.05 (-1.41%)
$-0.05 (-1.41%)
Prev Close
$3.55
$3.55
Open
$3.50
$3.50
Day's High
$3.50
$3.50
Day's Low
$3.50
$3.50
Volume
569
569
Avg. Vol
13,614
13,614
52-wk High
$6.85
$6.85
52-wk Low
$2.78
$2.78
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.51 | -0.393 |
| Sep '17 | 0.33 | -0.416 | |
| Jun '17 | 0.26 | -0.474 | |
| Mar '17 | 0.39 | -0.446 | |
| FY 2016 | Dec '16 | 0.10 | -0.378 |
| Sep '16 | 0.45 | -0.434 | |
| Jun '16 | 0.59 | -0.427 | |
| Mar '16 | 0.69 | -0.437 |
*Note: Units in Millions ofEuro
**Note: Units in Euro
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 2 | 0.56 | 1.00 | 0.12 | -- |
| Quarter Ending Sep-18 | 2 | 0.68 | 1.00 | 0.37 | -- |
| Year Ending Dec-18 | 2 | 2.23 | 3.00 | 1.47 | 1.11 |
| Year Ending Dec-19 | 2 | 4.70 | 4.90 | 4.50 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 2 | -0.45 | -0.40 | -0.49 | -- |
| Quarter Ending Sep-18 | 2 | -0.45 | -0.39 | -0.50 | -- |
| Year Ending Dec-18 | 2 | -1.79 | -1.53 | -2.05 | -2.13 |
| Year Ending Dec-19 | 2 | -1.74 | -1.32 | -2.16 | -3.26 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 188.22 | 33.60 | |
| P/E High - Last 5 Yrs. | -- | 284.72 | 45.95 | |
| P/E Low - Last 5 Yrs. | -- | 95.76 | 24.93 | |
| Beta | 0.55 | 0.75 | 0.80 | |
| Price to Sales (TTM) | 61.70 | 136.15 | 7.07 | |
| Price to Book (MRQ) | 2.67 | 19.54 | 5.13 | |
| Price to Tangible Book (MRQ) | 2.35 | 24.07 | 6.73 | |
| Price to Cash Flow (TTM) | -- | 122.99 | 25.52 | |
| % Owned Institutions | 55.76 | 11.18 | 2.22 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.28 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.75 | |
| Dividend 5 Year Growth Rate | -- | 1.94 | 3.93 | |
| Payout Ratio(TTM) | -- | 9.18 | 20.35 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 396.12 | 103.73 | 9.02 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -18.22 | 79.72 | 10.83 | |
| Sales - 5 Yr. Growth Rate | -- | 33.87 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -3.96 | -66.87 | 22.25 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -3.20 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 47.46 | 10.26 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 45.48 | 10.37 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.63 | 2.53 |
| Current Ratio (MRQ) | 5.95 | 5.97 | 3.62 |
| LT Debt to Equity (MRQ) | 13.42 | 23.32 | 11.31 |
| Total Debt to Equity (MRQ) | 18.40 | 25.75 | 13.97 |
| Interest Coverage (TTM) | -- | -186.61 | 30.11 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 36.56 | 54.01 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.38 | 52.12 | |
| EBITD Margin (TTM) | -2,637.66 | -- | -- | |
| EBITD - 5 Yr. Avg | -1,772.35 | -152.18 | 15.89 | |
| Operating Margin (TTM) | -2,708.90 | -563.03 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | -1,814.43 | -164.18 | 11.25 | |
| Pre-Tax Margin (TTM) | -2,921.27 | -535.84 | 4.97 | |
| Pre-Tax Margin - 5 Yr. Avg. | -1,702.99 | -171.12 | 11.56 | |
| Net Profit Margin (TTM) | -2,921.41 | -524.81 | 1.58 | |
| Net Profit Margin - 5 Yr. Avg. | -1,703.02 | -171.01 | 7.89 | |
| Effective Tax Rate (TTM) | -- | -0.44 | 31.30 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.14 | 24.27 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 14,129 | 23,887,722 | 816,988,634 | |
| Net Income/Employee (TTM) | -412,765 | 956,935 | 96,050,323 | |
| Receivable Turnover (TTM) | -- | 6.24 | 5.56 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.45 | |
| Asset Turnover (TTM) | 0.03 | 0.40 | 0.89 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -73.62 | -0.77 | 10.54 | |
| Return on Assets - 5 Yr. Avg. | -38.12 | 0.70 | 11.56 | |
| Return on Investment (TTM) | -84.41 | -0.74 | 13.19 | |
| Return on Investment - 5 Yr. Avg. | -41.17 | 4.20 | 14.97 | |
| Return on Equity (TTM) | -94.35 | -2.80 | 15.00 | |
| Return on Equity - 5 Yr. Avg. | -43.74 | -0.05 | 16.25 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -18.22 | 68.41 | -- |
| EPS (TTM) % | -2.67 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for ProQR Therapeutics NV
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial
- BRIEF-Proqr Q4 Loss Per Share Eur 0.39
- BRIEF-ProQR And Galapagos Announce Research Collaboration
- BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa
- BRIEF-Proqr reports loss of EUR 0.42 per share
Institutional Holders
| % Shares Owned: | 55.76% |
| # of Holders: | 42 |
| Total Shares Held: | 17,798,636 |
| 3 Mo. Net Change: | 59,980 |
| # New Positions: | 1 |
| # Closed Positions: | 1 |
| # Increased Positions: | 2 |
| # Reduced Positions: | 1 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.